Leonardo DRS DRS Q1 2026 Earnings Transcript

Leonardo DRS posted a strong Q1 with revenue of $846 million, up 6% year over year, adjusted EBITDA of $105 million, up 28%, and adjusted EBITDA margin expanding 210 bps to 12.4%. Management raised full-year guidance to $3.9 billion-$3.975 billion in revenue and $515 million-$530 million in adjusted EBITDA, while lifting adjusted diluted EPS guidance to $1.26-$1.30. Backlog hit new records on a 17th consecutive quarter of at least 1x book-to-bill, and the company also landed a $533 million DAIRCM production contract.

Analysis

DRS is transitioning from a “budget beta” defense name into a more self-help story: the core re-rate should come from margin durability, not just top-line entitlement. The key second-order effect is that mix and execution are now doing more of the heavy lifting, which reduces sensitivity to headline defense appropriations and makes the stock less dependent on a single budget outcome. That usually supports multiple expansion, but only if investors believe the company can sustain elevated conversion as capex rises.

The hidden lever is working capital and production cadence. Management is effectively telling us that near-term FCF can stay choppy while it funds growth, but the business is still moving toward better cash conversion as backlog converts and receipts normalize. If that happens, the market may start valuing DRS more like a quasi-industrial compounder with defense visibility rather than a pure procurement-cycle trade.

The biggest beneficiary outside the name itself is the supply chain around sensors, propulsion, and specialty materials; the biggest loser is any prime/competitor with slower open-architecture adoption or weaker exposure to distributed sensing. The risk is that the current enthusiasm around backlog and geopolitical urgency causes the street to extrapolate too much too fast—especially if order timing slips, capex ramps faster than expected, or the Israeli operations narrative becomes a margin versus growth tradeoff. The more meaningful tell over the next 1-2 quarters is not revenue growth, but whether ASC book-to-bill inflects back above 1x while IMS margins hold in the mid-teens.

Contrarian view: consensus may be underappreciating how much of this is already visible in the backlog, while overestimating how linear the re-rating will be. If the stock has already priced in an upgrade cycle, the next leg likely needs either another order surprise or evidence that FCF turns consistently positive despite higher investment. That makes this a better medium-term quality-growth long than a chase-the-print momentum name.

Key Decisions for Investors

• Go long DRS on weakness over the next 1-2 sessions; use a 3-6 month horizon. Risk/reward improves if the stock sells off on near-term FCF noise, because the operating leverage story is intact while valuation is still likely discounting budget uncertainty.
• Pair trade: long DRS / short a lower-margin defense hardware peer with weaker backlog conversion and less software mix over 3-6 months. The thesis is that DRS deserves a premium if margin expansion and cash conversion remain the differentiators.
• Buy DRS call spreads 3-6 months out to express upside from a second-order re-rate without paying full premium for geopolitical headlines. This is preferable to outright calls if you expect volatility around budget headlines and capex commentary.
• If you already own DRS, trim only if book-to-bill or FCF deteriorates over the next two quarters; otherwise stay long through the next print. The risk to the bull case is not the budget, but execution slipping as production capacity expands.
• Monitor for an ASC order re-acceleration and positive FCF quarter as the trigger to add. Those are the two catalysts most likely to force multiple expansion rather than just confirm the current narrative.